Alto Neuroscience price target raised to $28 from $27 at BTIG

BTIG analyst Thomas Shrader raised the firm’s price target on Alto Neuroscience (ANRO) to $28 from $27 and keeps a Buy rating on the shares. The firm cites the Alto approach to precision psychiatry being focused on optimizing patient selection to match a candidate drug’s molecular mechanism to a specific disease-associated impairment in order to maximize treatment effects, further noting that the ALTO-101 trial in the cognitive impairment associated with schizophrenia, CIAS, seems an ideal test case, the analyst tells investors in a research note.